tetano
Editor, Senior Moderator
PLoS Pathog
. 2021 Feb 17;17(2):e1009225.
doi: 10.1371/journal.ppat.1009225. eCollection 2021 Feb.
SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
Nicholas Murgolo[SUP] 1 [/SUP], Alex G Therien[SUP] 2 [/SUP], Bonnie Howell[SUP] 3 [/SUP], Daniel Klein[SUP] 4 [/SUP], Kenneth Koeplinger[SUP] 5 [/SUP], Linda A Lieberman[SUP] 2 [/SUP], Gregory C Adam[SUP] 6 [/SUP], Jessica Flynn[SUP] 3 [/SUP], Philip McKenna[SUP] 3 [/SUP], Gokul Swaminathan[SUP] 2 [/SUP], Daria J Hazuda[SUP] 7 [/SUP], David B Olsen[SUP] 3 [/SUP]
Affiliations
Abstract
Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts.
. 2021 Feb 17;17(2):e1009225.
doi: 10.1371/journal.ppat.1009225. eCollection 2021 Feb.
SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
Nicholas Murgolo[SUP] 1 [/SUP], Alex G Therien[SUP] 2 [/SUP], Bonnie Howell[SUP] 3 [/SUP], Daniel Klein[SUP] 4 [/SUP], Kenneth Koeplinger[SUP] 5 [/SUP], Linda A Lieberman[SUP] 2 [/SUP], Gregory C Adam[SUP] 6 [/SUP], Jessica Flynn[SUP] 3 [/SUP], Philip McKenna[SUP] 3 [/SUP], Gokul Swaminathan[SUP] 2 [/SUP], Daria J Hazuda[SUP] 7 [/SUP], David B Olsen[SUP] 3 [/SUP]
Affiliations
- PMID: 33596266
- DOI: 10.1371/journal.ppat.1009225
Abstract
Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts.